InMed Pharmaceuticals (INM) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InMed Pharmaceuticals has bolstered its patent portfolio by securing three new U.S. patents, enhancing the protection and commercial viability of its innovative drug candidates for conditions with high unmet medical needs. These patents cover a range of areas, including the treatment of epidermolysis bullosa, a biosynthesis manufacturing process, and an ocular drug delivery formulation. This advancement reflects the company’s ongoing commitment to advancing its pipeline of proprietary small molecule drugs for a variety of serious health conditions.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.